Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, marking a significant step toward commercializing an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The advancement positions Oncotelic to potentially generate revenue through software licensing, automation deployment, manufacturing partnerships, and technology-enabled contract development and manufacturing services (CDMO).
According to the company, the Phase 2 deployment expands the capabilities of its proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. The integrated platform combines PDAOAI(TM) with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing, addressing industry needs for efficiency, quality, and compliance in sterile drug production.
The pharmaceutical manufacturing sector is increasingly adopting automation and artificial intelligence to reduce human error, lower costs, and accelerate production timelines. Oncotelic’s initiative could offer a scalable solution for contract manufacturers and pharmaceutical companies seeking to modernize their facilities. The company plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. Beyond its drug pipeline, the company leverages its AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. The company also owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. For more information about Oncotelic, visit the company’s newsroom at https://nnw.fm/OTLC.
The completion of Phase 2 objectives suggests Oncotelic is making tangible progress toward operationalizing its AI manufacturing platform, which could serve as a new revenue driver independent of its drug development pipeline. By targeting sterile injectable manufacturing—a high-demand, high-compliance area—the company may address a critical bottleneck in pharmaceutical production. The upcoming demonstration at BIO 2026 could attract potential partners or customers, further validating the platform’s commercial viability.
Investors and industry observers will be watching for updates on commercialization milestones, including any licensing agreements or CDMO contracts that may arise from the platform’s deployment. Oncotelic’s ability to execute on this initiative could enhance its valuation and provide a diversified revenue stream alongside its core drug development activities.
